In an adult with chronic kidney disease and an eGFR ≥25 mL/min/1.73 m², how should dapagliflozin be initiated, what is the appropriate dose, what monitoring is required, and what are the contraindications?

Dapagliflozin in CKD: Initiation, Dosing, Monitoring, and Contraindications

Initiate dapagliflozin 10 mg once daily in adults with CKD and eGFR ≥25 mL/min/1.73 m² to reduce the risk of kidney failure, cardiovascular death, and heart failure hospitalization, regardless of diabetes status. 1

Who Should Receive Dapagliflozin

The strongest indication exists for patients with:

• eGFR ≥20 mL/min/1.73 m² AND urine albumin-to-creatinine ratio (ACR) ≥200 mg/g (≥20 mg/mmol) - Grade 1A recommendation 1
• eGFR ≥20 mL/min/1.73 m² AND heart failure (any ejection fraction) - Grade 1A recommendation, regardless of albuminuria level 1

For patients with eGFR 20-45 mL/min/1.73 m² AND ACR <200 mg/g (<20 mg/mmol), initiation is suggested but with weaker evidence (Grade 2B) 1. Real-world data supports effectiveness even in this lower albuminuria population 2.

This applies to both diabetic and non-diabetic CKD patients 1, 3.

Dosing

Standard dose: 10 mg orally once daily for CKD indication 4

Key Dosing Thresholds:

• eGFR ≥25 mL/min/1.73 m²: Initiate at 10 mg daily 4
• eGFR <25 mL/min/1.73 m²: Do NOT newly initiate 5, 4
• If eGFR falls below 25 while on therapy: Continue treatment until dialysis initiation 5, 1, 4

The landmark DAPA-CKD trial demonstrated a 39% relative risk reduction in the composite of sustained eGFR decline ≥50%, end-stage kidney disease, or renal/cardiovascular death (HR 0.61,95% CI 0.51-0.72, NNT=19) 3. Importantly, benefits persisted even when eGFR declined below initiation thresholds during follow-up 6.

Special Consideration for Diabetes:

If using dapagliflozin for glycemic control (not CKD protection), do not initiate if eGFR <45 mL/min/1.73 m² as it becomes ineffective for glucose lowering 4.

Pre-Initiation Assessment

Before starting dapagliflozin:

1. Assess renal function - Measure eGFR and urine ACR 4
2. Evaluate volume status - Correct volume depletion before initiation 4
3. Check for contraindications (see below)

Monitoring Requirements

Standard CKD monitoring frequency does NOT need to change after starting dapagliflozin 1. The initial eGFR dip is expected and not harmful:

• Expect a reversible eGFR decrease of 3-5 mL/min/1.73 m² within the first 2 weeks 7
• This acute dip is hemodynamic, not nephrotoxic - patients experiencing >10% eGFR reduction at 2 weeks actually had better long-term kidney outcomes (slower eGFR decline: -1.58 vs -2.44 mL/min/1.73 m²/year) 7
• Do not discontinue due to this initial eGFR dip 1

Ongoing Monitoring:

• Continue routine CKD monitoring per standard of care
• Monitor blood pressure (expect modest reduction of ~3 mmHg systolic) 8
• Watch for signs of volume depletion, especially in elderly patients 4

Temporary Interruption

Withhold dapagliflozin for at least 3 days before major surgery or prolonged fasting to reduce ketoacidosis risk 1, 4. Resume when patient is clinically stable and eating normally.

Also withhold during:

• Critical medical illness
• Acute febrile illness
• Situations with increased ketosis risk 1

Contraindications

Absolute contraindication:

• History of serious hypersensitivity reaction (anaphylaxis, angioedema) to dapagliflozin 4

Do NOT initiate in:

• eGFR <25 mL/min/1.73 m² (though continue if already on therapy) 5, 4
• Patients on dialysis 5
• Polycystic kidney disease 5, 4
• Recent immunosuppressive therapy for kidney disease 4

Common Pitfalls to Avoid

1. Don't stop dapagliflozin due to initial eGFR dip - This is expected and associated with better long-term outcomes 7
2. Don't withhold in elderly patients with appropriate eGFR - Benefits are consistent across age groups, though monitor for hypotension 4
3. Don't confuse glycemic control thresholds with CKD protection thresholds - CKD indication allows initiation down to eGFR 25, while diabetes indication requires eGFR ≥45 4
4. Don't discontinue when eGFR falls below 25 during treatment - Continue until dialysis starts 1, 4, 6
5. Don't forget to assess volume status first - Correct dehydration before starting 4

Clinical Context

The 2024 KDIGO guidelines provide the most authoritative framework 1, supported by robust trial data from DAPA-CKD 3 showing mortality benefit (HR 0.69,95% CI 0.53-0.88) and heart failure reduction (HR 0.71,95% CI 0.55-0.92). Real-world evidence confirms effectiveness extends to patients with lower albuminuria levels 2, and benefits persist even with deteriorating kidney function 6, 9.

The BMJ 2024 guideline emphasizes not initiating below eGFR 20 but continuing therapy if decline occurs 5, aligning with FDA labeling 4 and KDIGO recommendations 1.